—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Arrowhead Pharmaceuticals Inc (ARWR) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ARWR, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.82 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How ARWR has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.82 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Arrowhead Pharmaceuticals Inc moved 0.82% on average · correlation 0.12 · higher than 78% of US names
  • Beta, last 3 months 1.30 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.40% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −1.33% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ARWR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Arrowhead Pharmaceuticals Inc

ARWR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Arrowhead Pharmaceuticals develops RNA interference medicines aimed at chronic diseases, using its own delivery technology to silence disease-causing genes in the liver and other tissues. Its pipeline covers candidates for lipid disorders, kidney disease and other conditions, several partnered with larger drugmakers such as Takeda, Amgen and GlaxoSmithKline. It is based in Pasadena, California.
Where it sits in the stack
Arrowhead carries no seat in our indices; it sits in the Healthcare sector of Closelooknet's US universe, grouped with clinical-stage biotechnology names developing RNA interference therapeutics for chronic disease, rather than in any AI infrastructure sleeve.
Who it is priced against
The peer group draws on other scored healthcare names based in the US, including Regeneron, Vertex and BeiGene; the market also compares Arrowhead with Alnylam Pharmaceuticals as another RNA interference developer.
Why Closelooknet tracks it
Arrowhead carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in its editions.
What the diary watches
The diary watches whether pipeline candidates advance through their trial phases and whether partner collaborations expand, since either would alter the read on the shares.

Arrowhead Pharmaceuticals Inc (ARWR) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Arrowhead Pharmaceuticals Inc (ARWR)?

Arrowhead Pharmaceuticals Inc trades as ARWR on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is ARWR in a Closelooknet index?

Not currently — Arrowhead Pharmaceuticals Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does ARWR trade against its moving averages?

Mixed moving-average stack: Trades -22.9% vs the 50-day and -15.1% vs the 200-day average, 35.6% below the 52-week high and +77.8% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Arrowhead Pharmaceuticals Inc compare with its peers?

Against its peer group (Biotechnology · US), Arrowhead Pharmaceuticals Inc (ARWR) sits 35.6% below its 52-week high, 22.9% below its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to ARWR in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Arrowhead Pharmaceuticals Inc trade when bond yields rise?

Over the past year Arrowhead Pharmaceuticals Inc had a beta of 0.82 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 78% of US names. On the 10 sessions in which long bonds fell most it moved −0.40% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Arrowhead Pharmaceuticals Inc do?

Arrowhead Pharmaceuticals develops RNA interference medicines aimed at chronic diseases, using its own delivery technology to silence disease-causing genes in the liver and other tissues. Its pipeline covers candidates for lipid disorders, kidney disease and other conditions, several partnered with larger drugmakers such as Takeda, Amgen and GlaxoSmithKline. It is based in Pasadena, California. The peer group draws on other scored healthcare names based in the US, including Regeneron, Vertex and BeiGene; the market also compares Arrowhead with Alnylam Pharmaceuticals as another RNA interference developer.

Where does Arrowhead Pharmaceuticals Inc sit in the AI build-out?

Arrowhead carries no seat in our indices; it sits in the Healthcare sector of Closelooknet's US universe, grouped with clinical-stage biotechnology names developing RNA interference therapeutics for chronic disease, rather than in any AI infrastructure sleeve. Arrowhead carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in its editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for ARWR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.